These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Iodine-125-brachytherapy of malignant choroid melanoma. II: Long-term functional outcome].
    Author: Kreissig I, Rose D, Simader E.
    Journal: Klin Monbl Augenheilkd; 1996 Jul; 209(1):7-12. PubMed ID: 8965481.
    Abstract:
    BACKGROUND: Following I-125 brachytherapy of choroidal melanoma, a good primary postoperative visual acuity results. The aim of this study is to evaluate postoperative, longterm visual acuity answering the following questions: 1) When do radiogenic complications begin to develop; 2) How long does the postoperative visual acuity remain stable; 3) Is there a difference if the treated tumor is < or = or > 3 mm off the disc and foveola respectively. PATIENTS AND METHODS: Between 12/1984-12/1989, 19 patients were treated with I-125 brachytherapy for choroidal melanoma. Height of tumor was x 5.8 mm, maximum base diameter x 11.6 mm. In 10 eyes (group A), the posterior tumor border was < or = 3 mm off the disc and foveola respectively, in 9 (group B) > 3 mm. The plaque was in situ x 7.5 days, apical radiation dose x 70 Gy, and scleral contact dose x 355 Gy. Follow-up ranged at x 6.3 years. RESULTS: Between preoperative visual acuity in group A and group B there was a statistically significant difference (p < 0.05), which remained stable 1 1/2 years postoperatively. Subsequent deterioration of visual acuity occurred later in group B than in group A, but was present after 4 1/2 years in all patients and ranged at < or = 20/400. This decrease was due to subsequent radiogenic oculopathy. CONCLUSIONS: Radiogenic complications following I-125 brachytherapy begin within the first 6 months. In group B visual acuity deteriorated later, but after 4 1/2 years, it decreased due to radiogenic oculopathy to 20/400 in all patients. Prospective longterm studies are needed to evaluate whether I-125 should be indicated for larger melanomas and Ruthenium-106 for smaller melanomas to obtain better longterm visual results.
    [Abstract] [Full Text] [Related] [New Search]